unyango olutsha olungelulo oluncinci lomhlaza wemiphunga

Umhlaza wemiphunga yeseli engeyiyo encinci (NSCLC) ngoyena nobangela uphambili wokusweleka okunxulumene nomhlaza kwihlabathi liphela. Ngethamsanqa, ukuqhubela phambili okubonakalayo kwiinketho zonyango kuyavela, kunika ithemba elitsha kwiziphumo eziphuculweyo kunye nomgangatho wobomi. Eli nqaku liphonononga yamva nje unyango olutsha olungelulo oluncinci lomhlaza wemiphunga, kubandakanywa unyango ekujoliswe kulo, i-immunotherapies, indibaniselwano ye-chemotherapy, kunye nezilingo ezintsha zekliniki.Ukuqonda uMhlaza ongeNcinci weCell Lung Cancer (NSCLC)Umhlaza wemiphunga ongeyiyo iseli encinci (NSCLC) lolona hlobo luxhaphakileyo lomhlaza wemiphunga, ubalelwa malunga ne-80-85% yazo zonke izifo zomhlaza wemiphunga. Ibandakanya iindidi ezincinci, kubandakanya i-adenocarcinoma, i-squamous cell carcinoma, kunye ne-cell carcinoma enkulu. Inqanaba le-NSCLC ekuxilongeni lichaphazela kakhulu ukhetho lonyango kunye ne-prognosis. I-NSCLC yasekuqaleni inokunyangwa ngotyando, ngelixa izigaba eziphambili zihlala zifuna indibaniselwano yonyango.Ii-NSCLC zonyango ezijoliswe kuzo ziziyobisi ezijolise ngokukodwa kwiiprotheni ezithile okanye iijini ezifaka isandla ekukhuleni kweeseli zomhlaza kunye nokuphila. Olu nyango luhlala lusebenza ngakumbi kwaye luneziphumo ebezingalindelekanga ezimbalwa kunechemotherapy yesintu. Iithagethi eziqhelekileyo kwi-NSCLC ziquka i-EGFR, i-ALK, i-ROS1, i-BRAF, kunye ne-MET.EGFR InhibitorsI-Epidermal growth factor receptor (EGFR) yiprotheni enceda iiseli zikhule kwaye zihlule. Ezinye iithumba ze-NSCLC zineenguqu kwi-EGFR gene, ekhokelela ekukhuleni kweeseli ezingalawulwayo. I-EGFR inhibitors, njenge-gefitinib, i-erlotinib, i-afatinib, kunye ne-osimertinib, ivimba umsebenzi we-EGFR, ukunciphisa okanye ukuyeka ukukhula kwe-tumor.Izibonelelo: Ihlala isebenza kwizigulane ezinokuguqulwa kwe-EGFR, ekhokelela ekuphuculweni kokusinda kunye nomgangatho wobomi.Iziphumo ebezingalindelekanga: I-Skin rash, i-diarrhea, i-fatigue.I-Osimertinib idla ngowona nyango olukhethiweyo lokuqala lwe-EGFR-mutated NSCLC, ebonisa ukusebenza kakuhle okuphezulu xa kuthelekiswa ne-EGFR inhibitors yesizukulwana sangaphambili. Unokufunda ngakumbi malunga ne-EGFR inhibitors kwi Iwebhusayithi ye-American Cancer Society.ALK InhibitorsAnaplastic lymphoma kinase (ALK) yenye iprotheni enokuguqulwa kwi-NSCLC. I-ALK inhibitors, njenge-crizotinib, i-ceritinib, i-alectinib, i-brigatinib, kunye ne-lorlatinib, ijolise kwiprotheni ye-ALK, inqanda umsebenzi wayo kunye nokukhusela ukukhula kwe-tumor.Izibonelelo: Ukuphumelela kwizigulane ezine-ALK rearrangements, okubangelwa ukuphuculwa kokusinda kunye nokunciphisa ukuqhubela phambili kwesifo.Iziphumo ebezingalindelekanga: Utshintsho lombono, isicaphucaphu, ukuhlanza, isifo sohudo, ukudinwa.I-Alectinib kunye ne-Lorlatinib zihlala zikhethwa kunyango lokuqala ngenxa yokuphucula ukusebenza kwazo kunye nokukwazi ukungena kumqobo wegazi-ingqondo, ebalulekileyo kwizigulane ezine-brain metastases. Uphando lomhlaza e-UK inika ulwazi olongezelelweyo.I-ROS1 InhibitorsROS1 yi-receptor tyrosine kinase ethi, xa idibene nenye i-gene, inokuqhuba ukukhula komhlaza. I-ROS1 inhibitors, njenge-crizotinib kunye ne-entrectinib, isetyenziselwa ukuphatha i-NSCLC kunye ne-ROS1 fusions.Izibonelelo: I-tumor shrinkage ebalulekileyo kunye nokuphila ixesha elide kwizigulana ezine-ROS1-positive NSCLC.Iziphumo ebezingalindelekanga: Ngokufana ne-ALK inhibitors.I-Entrectinib ibonise isithembiso ngenxa yokukwazi ukuwela umqobo wegazi-ubuchopho, okwenza kube nempumelelo ekuphatheni i-metastases yengqondo. Jonga i Iwebhusayithi ye-Arhente yaMayeza yaseYurophu ngolwazi oluthe kratya.I-Immunotherapy ye-NSCLCImmunotherapy ibopha amandla amajoni omzimba okulwa nomhlaza. I-Immune checkpoint inhibitors luhlobo lwe-immunotherapy oluvimbela iiprotheyini ezithintela amajoni omzimba ekuhlaseleni iiseli zomhlaza.PD-1/PD-L1 InhibitorsProgrammed cell death protein 1 (PD-1) kunye neprogramed death-ligand 1 (PD-L1) ziiprotheyini ezinceda iiseli zomhlaza ukuba ziphephe amajoni omzimba. I-PD-1/PD-L1 inhibitors, njenge-pembrolizumab, nivolumab, atezolizumab, kunye ne-durvalumab, ivimba ezi proteni, ivumela amajoni omzimba ukuba aqaphele kwaye ahlasele iiseli zomhlaza.Izibonelelo: Iimpendulo ezihlala ixesha elide kunye nokuphuculwa kokusinda kwi-subset yezigulane ezine-NSCLC.Iziphumo ebezingalindelekanga: Iziphumo zecala ezinxulumene ne-immune, ezifana ne-pneumonitis, i-colitis, kunye ne-hepatitis.I-Pembrolizumab isoloko isetyenziswa njengonyango lokuqala lwezigulane ze-NSCLC ezine-PD-L1 ibonakaliso. Ulwazi oluninzi lunokufumaneka kwi Iwebhusayithi ye-FDA.CTLA-4 InhibitorsCytotoxic T-lymphocyte-associated protein 4 (CTLA-4) yenye iprotheyini ekwazi ukucinezela amajoni omzimba. I-Ipilimumab yi-CTLA-4 inhibitor enokuthi isetyenziswe ngokudibanisa ne-PD-1 inhibitors ukunyusa impendulo yokuzivikela kwiiseli zomhlaza.Izibonelelo: Inokuphucula ukusinda xa idibene ne-PD-1 inhibitors.Iziphumo ebezingalindelekanga: Iziphumo ezibaluleke ngakumbi ezinxulumene ne-immune-inhibitors xa kuthelekiswa ne-PD-1 inhibitors yodwa.I-Chemotherapy CombinationsNgelixa iindlela zonyango ezijoliswe kuzo kunye ne-immunotherapies ziye zaguqula unyango lwe-NSCLC, i-chemotherapy ihlala iyindlela ebalulekileyo, ngakumbi ngokudibanisa nolunye unyango. Unyango olutsha olungelulo oluncinci lomhlaza wemiphunga ihlala ibandakanya ukudibanisa ichemotherapy kunye ne-immunotherapy okanye unyango olujoliswe kuyo ukuphucula ukusebenza kwawo. unyango olutsha olungelulo oluncinci lomhlaza wemiphunga. Le ndlela yokwandisa amandla e-chemotherapy ukonakalisa iiseli zomhlaza kunye nokukhulula ii-antigens, zibenze babe sesichengeni sohlaselo lomzimba. Ukongezwa kwe-immunotherapy kunokwandisa impendulo yomzimba, ekhokelela kwiziphumo eziphuculweyo.Izibonelelo: Amazinga aphuculweyo okusinda kunye neempendulo xa kuthelekiswa nechemotherapy yedwa.Iziphumo ebezingalindelekanga: Ukonyuka komngcipheko we-chemotherapy kunye nemiphumo emibi enxulumene nomzimba.Unyango olujoliswe kuyo kunye ne-Chemotherapy CombinationsKwiimeko ezithile, ukudibanisa unyango olujoliswe kuyo kunye ne-chemotherapy kunokuba luncedo, ngakumbi kwizigulane eziye zaphuhliswa ukuchasana nonyango olujoliswe kuyo kuphela. Le ndlela inokunceda ukoyisa iindlela zokumelana nokuphucula iziphumo zonyango.Izibonelelo: Inokubuyisela ubuntununtunu kunyango olujoliswe kuyo kwaye iphucule ukusinda.Iziphumo ebezingalindelekanga: Umngcipheko owandileyo weziphumo ebezingalindelekanga kuwo omabini amayeza.Iilingo zeKlinikhi: Ikamva le-NSCLC TreatmentUlingo lweKlinikhi luphononongo lophando oluvavanyayo. unyango olutsha olungelulo oluncinci lomhlaza wemiphunga kunye namaqhinga. Ukuthatha inxaxheba kulingo lwezonyango kunokubonelela ngofikelelo kunyango lwe-cutting-edge olungekafumaneki ngokubanzi. I-Shandong Baofa Cancer Research Institute izibophelele ekuqhubeleni phambili uphando lomhlaza kwaye ibonelela ngeenkonzo kwaye ithatha inxaxheba kulingo lwezonyango olubonelela ngokufikelela kunyango oluphambili olungekafumaneki ngokubanzi. Funda ngakumbi malunga nolingo lwezonyango eShandong Baofa Cancer Research Institute.Unyango olusakhulayo kwiiLingo zeKlinikhiZininzi ezithembisayo unyango olutsha olungelulo oluncinci lomhlaza wemiphunga ngoku ziyavavanywa kulingo lwezonyango, kubandakanywa:I-antibody-drug conjugates (ADCs): La machiza ahambisa ichemotherapy ngokuthe ngqo kwiiseli zomhlaza, ukunciphisa umonakalo kwiiseli eziphilileyo.Ii-antibodies ezikhethekileyo: Ezi zithinteli zibophelela kuzo zombini iiseli zomhlaza kunye neeseli zokhuselo lomzimba, zizidibanisa ukuze ziphucule ukusabela komzimba.Unyango lweSellula (umzekelo, unyango lweseli ye-CAR-T): Ezi zonyango zibandakanya ukuguqula iiseli ze-immune ekujoliseni nasekutshabalaliseni iiseli zomhlaza.Ukuphila kunye ne-NSCLC: Izibonelelo kunye neNkxasoUkuphila kunye ne-NSCLC kunokuba ngumngeni, kodwa izibonelelo ezininzi kunye namaqela enkxaso akhoyo ukuze ancede izigulane kunye neentsapho zabo zijamelane nesifo. Cinga ngokujonga izixhobo ezivela kwimibutho efana ne Umbutho wamaLung waseMelika okanye i LUNGevity Foundation.Ukuziphendulela: Eli nqaku lenzelwe iinjongo zolwazi kuphela kwaye akufanele lithathwe njengengcebiso yezonyango. Nceda udibane nomboneleli wakho wezempilo malunga neengcebiso zonyango olulolwakho.